# Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)

> **NCT07719556** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 39 (estimated)

## Conditions studied

- Mantle Cell Lymphoma (MCL)

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** Obinutuzumab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07719556
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2029-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07719556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07719556, "Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07719556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*